Entropy Technologies LP Buys 13,899 Shares of Biogen Inc. $BIIB

Entropy Technologies LP increased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 576.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 16,312 shares of the biotechnology company’s stock after buying an additional 13,899 shares during the period. Entropy Technologies LP’s holdings in Biogen were worth $2,871,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Caprock Group LLC acquired a new stake in Biogen in the 3rd quarter worth about $742,000. Generali Investments Management Co LLC raised its position in shares of Biogen by 408.2% in the 3rd quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock valued at $1,397,000 after buying an additional 8,008 shares in the last quarter. SG Americas Securities LLC lifted its stake in Biogen by 1,793.8% in the 4th quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock valued at $32,352,000 after purchasing an additional 174,122 shares during the last quarter. TD Asset Management Inc raised its position in Biogen by 12.7% in the third quarter. TD Asset Management Inc now owns 161,195 shares of the biotechnology company’s stock valued at $22,580,000 after purchasing an additional 18,168 shares during the last quarter. Finally, K.J. Harrison & Partners Inc bought a new stake in Biogen during the 3rd quarter worth approximately $1,553,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Biogen stock opened at $200.05 on Monday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The firm’s fifty day moving average is $188.73 and its 200 day moving average is $184.37. The company has a market capitalization of $29.54 billion, a PE ratio of 21.46 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the company earned $3.02 EPS. Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BIIB. JPMorgan Chase & Co. boosted their target price on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Weiss Ratings raised shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Wedbush boosted their target price on shares of Biogen from $191.00 to $196.00 and gave the stock a “neutral” rating in a report on Thursday, April 30th. The Goldman Sachs Group boosted their target price on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Finally, Morgan Stanley boosted their target price on shares of Biogen from $200.00 to $206.00 and gave the stock an “equal weight” rating in a report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $217.26.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.